Tandem myeloablative ¹³¹I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients

By Deshayes Emmanuel   Kraeber-Bodéré Françoise   Vuillez Jean-Philippe   Bardiès Manuel   Teulon Isabelle   Pouget Jean-Pierre  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1283-1286

Future Medicine

Access to resources Recommend Favorite

Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma

By Kim Seon-Kyeong   Song Moo-Kon   Chung Joo   Shin Ho-Jin  

International Journal of Hematology, Vol. 98, Iss. 5, 2013-11 ,pp. : 543-548

Springer Publishing Company

Access to resources Recommend Favorite

Conditioning with treosulfan and fludarabine for patients with refractory or relapsed nonHodgkin lymphoma

By                            

Molecular and Clinical Oncology, Vol. 2, Iss. 5, 2014-01 ,pp. : 773-782

Spandidos Publications

Access to resources Recommend Favorite

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease

By Querellou Solène   Valette Frédéric   Bodet-Milin Caroline   Oudoux Aurore   Carlier Thomas   Harousseau Jean-Luc   Chatal Jean-François   Couturier Olivier  

Annals of Hematology, Vol. 85, Iss. 11, 2006-11 ,pp. : 759-767

Springer Publishing Company

Access to resources Recommend Favorite

Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country?

By Ruiz-Delgado Guillermo J   Gómez-Almaguer David   Tarín-Arzaga Luz C   Cantú-Rodriguez Olga G   Urdaneta Carlos Alarcón   Rodríguez-Morales Uxmal   Calderón-Garcia Jackeline   Fernández-Vargas Omar   Montes-Montiel Maryel   Sánchez-Cárdenas Mónica   Ruiz-Argüelles Guillermo J  

Hematology, Vol. 17, Iss. 4, 2012-07 ,pp. : 193-197

Maney Publishing

Access to resources Recommend Favorite